[Medicine heaven and earth] 294 drugs have been rejected and disqualified from the Internet! Lunan Beite, Huahai pharmaceutical, Qilu, Shuanglu, Hunan Dino and Dongting pharmaceutical have all entered the list

It's a long way to go I'll go up and down to find out - a large number of abandoned drug labels in Lisao by Qu Yuan In Ningxia and Tibet autonomous regions, enterprises have been affected by the disaster, and 282 drug online qualifications have been cancelled 175 enterprises have been frustrated, and some of them have been "listed" on the list of bad records Recently, the national drug supply and security integrated management information platform issued the notice of Ningxia on canceling the qualification of 263 drug manufacturers to win the bid (online) according to the drug procurement center of Ningxia Hui Autonomous Region public resources trading administration The qualification of 212 drug products that are not supplied or supplied abnormally will be cancelled, and the qualification of 4 drug manufacturers with inferior drug record will be cancelled According to the announcement, 212 drugs were disqualified from the Internet due to non supply or abnormal supply, and all medical institutions were required to select other winning (online) drugs to replace the abandoned (offline) drugs according to the clinical diagnosis and treatment practice, or according to the policies of drug record purchase and short and short drug purchase in our district, to ensure the clinical use of drugs All drug distribution enterprises shall actively contact with drug manufacturers, purchase and distribute drugs in sufficient quantity, and ensure the drug supply of medical institutions It is not groundless that Ningxia cancelled the qualification of more than 100 drugs to be put on the Internet this time, but the result of policy guidance As early as March 7, 2018, the office of health and Family Planning Commission of Ningxia autonomous region issued the notice on printing and distributing the key points of drug supply security work in 2018, which pointed out that it is required to strengthen the supervision and management of drug supply security and the guidance of the general office of the State Council on improving the centralized drug procurement work in public hospitals Establish a more open, more conducive to market competition drug distribution enterprise filing management system We will improve the supervision and assessment system for distribution enterprises and medical institutions, and implement the work standards for supervision and management of drug supply security in Ningxia Hui Autonomous Region The coverage of supervision and management of drug supply security will not be less than 95%, and the drug distribution rate will not be less than 85% At the same time, the announcement stated that the autonomous region should further establish a system to guarantee the supply of drugs in short supply, include all public hospitals above the second level in the region, township hospitals and community health service institutions into the scope of monitoring the shortage of drugs, establish a management system for the list of drugs in short supply, and guarantee the supply of drugs in short supply for medical institutions It can be seen that the benefits of the filing management system and the centralized purchasing information management system of drugs (medical consumables) are relatively high, which can not only supervise and assess the medical institutions and distribution enterprises, but also reflect the guarantee efficiency of the normal supply of drugs by the production enterprises or bidding enterprises In case of abnormal drug supply, relevant organizations can take corresponding measures with evidence (list of abandoned drugs, see Figure 1 and Figure 2 for details) Figure 1: Ningxia cancels the qualification list of four pharmaceutical manufacturers with inferior drug record and 51 pharmaceutical product specifications winning the bid (online) Figure 2: Ningxia cancels the qualification list of 212 pharmaceutical product specifications not supplied or not normally supplied In the middle of June, the drug purchase service management center of Tibet Autonomous Region issued the announcement on canceling the qualification of winning the bidding and networking for some drugs such as azithromycin for injection The announcement directly resulted in the disqualification of 19 drugs, including azithromycin for injection, calcium folinate for injection, thymopentin injection, etc Drug rejection is a common situation in centralized purchase, but at the same time, enterprises are branded with bad records, which is equivalent to driving them out of the drug competition market in the autonomous region (Note: the penalty period is 2 years rather than permanent expulsion) The author's judgment can be supported by the notice on registration of online drug centralized purchase and distribution enterprises of public medical and health institutions in Tibet Autonomous Region in 2017 and the measures for the management of adverse behaviors of centralized drug purchase in Tibet Autonomous Region issued on September 24, 2017 The announcement clearly points out that there are two penalties for adverse records of enterprises: ① cancel the bid winning / hanging of all products of illegal enterprises The online centralized purchase application of any product will not be accepted within 2 years; ② the bid winning / Networking qualification of the corresponding product of the illegal enterprise will be cancelled, and the online centralized purchase application of the corresponding product will not be accepted within 2 years In addition, the attachment shows that the reasons for disqualification include: 1 The raw material provided by the enterprise is unqualified and cannot be produced and supplied normally; 2 The enterprise applies for withdrawal of the bid; 3 The enterprise provides the materials which cannot be supplied normally Among them, 2 drugs were only disqualified from the network, 16 drugs were disqualified from the network, (enterprises) were recorded with bad records, and 1 "lucky" drug was disqualified from the double envelope bid winning qualification and included in the network limited purchase See Figure 3 for details Figure 3: information about other hot spots in the list of drugs disqualified from winning the bid and online trading: 1 There are 12 drugs to suspend online trading qualification in Zhejiang Province this week, including compound α - ketoacid tablets of Beijing Wansheng Pharmaceutical Co., Ltd and burofen granules of Ouyi Pharmaceutical Co., Ltd of Shiyao group In addition, the company suspended the qualification of online transaction of imipenem cilastatin sodium for injection (see Fig 4 and 5 for details) Fig 4: 11 drugs to be suspended from online trading qualification Fig 5: suspension of online trading qualification of imipenem and cilastatin sodium for injection of India's Lambertian Pharmaceutical Co., Ltd 2 Great changes in quality types of Hainan's centralized procurement The quality types of Beijing Shuanglu and Xiamen Tebao were adjusted from "type II" to "type IV" due to the establishment of complaints (see Figure 6 for details) Figure 6: quality type audit results of some varieties